Consent to the Distribution of New Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution inNew Zealand of the new medicines set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Dicloxacillin sodium, anhydrous 559 mg, 1.117 g, 2.235 g equivalent to 500 mg, 1 g, 2 g dicloxacillin respectively Powder for injection, vial Bristol-Myers Squibb SpA., Sermoneta, Latina, Italy Diclocil Dicloxacillin sodium, anhydrous equivalent to 62.5 mg/5 mL, 125 mg/5 mL dicloxacillin in 100 mL Powder for oral suspension Bristol-Myers Squibb SpA., Sermoneta, Latina, Italy Diclocil Dicloxacillin sodium, anhydrous 275 mg, 551 mg, equivalent to 250 mg, 500 mg dicloxacillin respectively Capsules Bristol-Myers Squibb SpA., Sermoneta, Latina, Italy Diclocil Tamoxifen citrate 10 mg, 20 mg Tablets Egis Pharmaceuticals, Budapest, Hungary Estroxyn Insulin lispro (rDNA origin) 100 U/mL in 10 mL Injection, vial Lilly France S A., Fegersheim, France Humalog Insulin lispro (rDNA origin) 100 U/mL in 1.5 mL Injection, cartridge Lilly France S A., Fegersheim, France Humalog Each 0.5 mL dose contains 8 mcg formalin treated 69 kDa outer membrane protein of B. pertussis, NLT 30 IU adsorbed diphtheria toxoid, 25 mcg formalin treated filamentous haemagglutinin, 25 mcg detoxified pertussis toxin, and NLT 40 IU adsorbed tetanus toxoid Vaccine, prefilled syringe Sachsisches Serumwerk GmbH., Dresden, Germany and SmithKline Beecham Biologicals, Rixensart, Belgium Infanrix Each 0.5 mL dose contains 8 mcg formalin treated 69 kDa outer membrane protein of B. pertussis, NLT 30 IU adsorbed diphtheria toxoid, 25 mcg formalin treated filamentous haemagglutinin, 25 mcg detoxified pertussis toxin, and NLT 40 IU adsorbed tetanus toxoid Vaccine, vial Sachsisches Serumwerk GmbH., Dresden, Germany and SmithKline Beecham Biologicals, Rixensart, Belgium Infanrix Coal tar, prepared 10 mg/g in 100 mL, 250 mL Gel, topical Divpharm Manufacturing and Packaging Co., Longdale, Johannesburg, South Africa Linotar Gel 1 Coal tar, prepared 20 mg/g in 100 mL, 250 mL Gel, topical Divpharm Manufacturing and Packaging Co., Longdale, Johannesburg, South Africa Linotar Gel 2 Each 0.5 mL dose contains at least 1000 TCID live measles virus (edmonston zagreb 19 strain) Vaccine, vial and solvent in syringe or ampoule Swiss Serum & Vaccine Institute, Berne, Switzerland Moraten Berna Desirudin 15 mg and difuent Powder for injection, vial and diluent, ampoule Ciba-Geigy AG, Stein, Switzerland Revasc Each 0.5 mL dose contains at least 1000 TCID live measles virus (edmonston zagreb 19 strain), 5000 TCID mumps virus (Rubini strain) and 1000 TCID Rubella virus (Wistar RA27/3 strain) Vaccine, vial and solvent in syringe or ampoule Swiss Serum & Vaccine Institute, Berne, Switzerland Triviraten Berna Dated this 25th day of November 1996. KAREN O. POUTASI (Dr), Director-General of Health, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.